Loading clinical trials...
Loading clinical trials...
A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN
Conditions
Interventions
Pegylated Interferon and Ribavirin
Start Date
October 1, 2001
Completion Date
December 1, 2002
Last Updated
May 19, 2011
NCT05012111
NCT03520647
NCT05447442
NCT06953479
NCT06287268
NCT04645199
Lead Sponsor
Ortho Biotech Products, L.P.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions